Thiogenesis Therapeutics, Corp. (TTIPF)

US Markets

$0.42 +0.00%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History -3.1% over period

About Thiogenesis Therapeutics, Corp.

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.